Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulka Vaishampayan

Showing results (161-170 of 176) with videos related to

Pageof 18
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|April 1, 2024
Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancerTongchen He, Caleb Cheng, Yuanyuan Qiao, et al.
Cancer|March 25, 2021
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)Michael R Harrison, Brian A Costello, Nrupen A Bhavsar, et al.
Nature Genetics|October 3, 2025
Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancerJie Luo, Zhixiang Chen, Yuanyuan Qiao, et al.
Nature Communications|April 7, 2022
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trialMichiel S van der Heijden, Thomas Powles, Daniel Petrylak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2016
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion StudyLucia Nogova, Lecia V Sequist, Jose Manuel Perez Garcia, et al.
Clinical Genitourinary Cancer|March 23, 2017
Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter AnalysisAndrea Necchi, Gregory R Pond, Daniele Raggi, et al.
European Urology|January 24, 2025
A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer TypesAxel Bex, Michael Jewett, Bryan Lewis, et al.
Nature|December 23, 2021
Targeting SWI/SNF ATPases in enhancer-addicted prostate cancerLanbo Xiao, Abhijit Parolia, Yuanyuan Qiao, et al.
Cancer Discovery|June 1, 2018
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> AlterationsSumanta K Pal, Jonathan E Rosenberg, Jean H Hoffman-Censits, et al.
Cancer|August 3, 2021
Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statementGennady Bratslavsky, Neil Mendhiratta, Michael Daneshvar, et al.
Pageof 18

Showing results (161-170 of 176) with videos related to

Sort By:
Pageof 18
Proceedings of the National Academy of Sciences of the United States of America|April 1, 2024
Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancerTongchen He, Caleb Cheng, Yuanyuan Qiao, et al.
Cancer|March 25, 2021
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)Michael R Harrison, Brian A Costello, Nrupen A Bhavsar, et al.
Nature Genetics|October 3, 2025
Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancerJie Luo, Zhixiang Chen, Yuanyuan Qiao, et al.
Nature Communications|April 7, 2022
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trialMichiel S van der Heijden, Thomas Powles, Daniel Petrylak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2016
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion StudyLucia Nogova, Lecia V Sequist, Jose Manuel Perez Garcia, et al.
Clinical Genitourinary Cancer|March 23, 2017
Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter AnalysisAndrea Necchi, Gregory R Pond, Daniele Raggi, et al.
European Urology|January 24, 2025
A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer TypesAxel Bex, Michael Jewett, Bryan Lewis, et al.
Nature|December 23, 2021
Targeting SWI/SNF ATPases in enhancer-addicted prostate cancerLanbo Xiao, Abhijit Parolia, Yuanyuan Qiao, et al.
Cancer Discovery|June 1, 2018
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> AlterationsSumanta K Pal, Jonathan E Rosenberg, Jean H Hoffman-Censits, et al.
Cancer|August 3, 2021
Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statementGennady Bratslavsky, Neil Mendhiratta, Michael Daneshvar, et al.
Pageof 18